Document is current
Any future updates will be listed below
-
Authors
Wang, Hejia Henry
Yarchoan, Mark https://orcid.org/0000-0003-4401-0748
- License Information
-
More Information
Article History
First Online: 22 September 2025
Competing interests
: M.Y. works in an institution that receives grants and/or research support from Bristol Myers Squibb, Exelixis, Genentech and Incyte; receives honoraria from AstraZeneca, Exelixis, Genetech, Incyte and Lantheus; is a co-inventor on filed and licensed patents related to therapeutic cancer vaccines and KRAS-related immunotherapies, including WO2024216241 (Heteroclitic Neoepitope Vaccines), WO2024216242 (Mutant KRAS-Specific TCRs) and WO2023220434 (Neoantigen Vaccines for Cancer Prevention), all patents are assigned to and managed by Johns Hopkins University and outside of the scope of the specific cancer vaccine discussed in this manuscript; and is a cofounder of and holds ownership interest in Adventris Pharmaceuticals. H.H.W. declares no competing interests.
